175 related articles for article (PubMed ID: 38064533)
21. Unexpected evolutionary benefit to phages imparted by bacterial CRISPR-Cas9.
Tao P; Wu X; Rao V
Sci Adv; 2018 Feb; 4(2):eaar4134. PubMed ID: 29457136
[TBL] [Abstract][Full Text] [Related]
22. Targeting of temperate phages drives loss of type I CRISPR-Cas systems.
Rollie C; Chevallereau A; Watson BNJ; Chyou TY; Fradet O; McLeod I; Fineran PC; Brown CM; Gandon S; Westra ER
Nature; 2020 Feb; 578(7793):149-153. PubMed ID: 31969710
[TBL] [Abstract][Full Text] [Related]
23. All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo.
Ibraheim R; Song CQ; Mir A; Amrani N; Xue W; Sontheimer EJ
Genome Biol; 2018 Sep; 19(1):137. PubMed ID: 30231914
[TBL] [Abstract][Full Text] [Related]
24. Diverse Mechanisms of CRISPR-Cas9 Inhibition by Type II Anti-CRISPR Proteins.
Hwang S; Maxwell KL
J Mol Biol; 2023 Apr; 435(7):168041. PubMed ID: 36893938
[TBL] [Abstract][Full Text] [Related]
25. A cell cycle-dependent CRISPR-Cas9 activation system based on an anti-CRISPR protein shows improved genome editing accuracy.
Matsumoto D; Tamamura H; Nomura W
Commun Biol; 2020 Oct; 3(1):601. PubMed ID: 33097793
[TBL] [Abstract][Full Text] [Related]
26. Exploitation of the Cooperative Behaviors of Anti-CRISPR Phages.
Chevallereau A; Meaden S; Fradet O; Landsberger M; Maestri A; Biswas A; Gandon S; van Houte S; Westra ER
Cell Host Microbe; 2020 Feb; 27(2):189-198.e6. PubMed ID: 31901522
[TBL] [Abstract][Full Text] [Related]
27. Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review).
Rodríguez-Rodríguez DR; Ramírez-Solís R; Garza-Elizondo MA; Garza-Rodríguez ML; Barrera-Saldaña HA
Int J Mol Med; 2019 Apr; 43(4):1559-1574. PubMed ID: 30816503
[TBL] [Abstract][Full Text] [Related]
28. Naturally Occurring Off-Switches for CRISPR-Cas9.
Pawluk A; Amrani N; Zhang Y; Garcia B; Hidalgo-Reyes Y; Lee J; Edraki A; Shah M; Sontheimer EJ; Maxwell KL; Davidson AR
Cell; 2016 Dec; 167(7):1829-1838.e9. PubMed ID: 27984730
[TBL] [Abstract][Full Text] [Related]
29. Rapid characterization of anti-CRISPR proteins and optogenetically engineered variants using a versatile plasmid interference system.
Song G; Tian C; Li J; Zhang F; Peng Y; Gao X; Tian Y
Nucleic Acids Res; 2023 Dec; 51(22):12381-12396. PubMed ID: 37930830
[TBL] [Abstract][Full Text] [Related]
30. Anti-CRISPR proteins trigger a burst of CRISPR-Cas9 expression that enhances phage defense.
Workman RE; Stoltzfus MJ; Keith NC; Euler CW; Bondy-Denomy J; Modell JW
Cell Rep; 2024 Mar; 43(3):113849. PubMed ID: 38427560
[TBL] [Abstract][Full Text] [Related]
31. Applications of Anti-CRISPR Proteins in Genome Editing and Biotechnology.
Kraus C; Sontheimer EJ
J Mol Biol; 2023 Jul; 435(13):168120. PubMed ID: 37100169
[TBL] [Abstract][Full Text] [Related]
32. [Mechanisms of the Specificity of the CRISPR/Cas9 System in Genome Editing].
Kulishova LM; Vokhtantsev IP; Kim DV; Zharkov DO
Mol Biol (Mosk); 2023; 57(2):269-284. PubMed ID: 37000655
[TBL] [Abstract][Full Text] [Related]
33. Inhibition mechanisms of CRISPR-Cas9 by AcrIIA17 and AcrIIA18.
Wang X; Li X; Ma Y; He J; Liu X; Yu G; Yin H; Zhang H
Nucleic Acids Res; 2022 Jan; 50(1):512-521. PubMed ID: 34893860
[TBL] [Abstract][Full Text] [Related]
34. Anti-CRISPR prediction using deep learning reveals an inhibitor of Cas13b nucleases.
Wandera KG; Alkhnbashi OS; Bassett HVI; Mitrofanov A; Hauns S; Migur A; Backofen R; Beisel CL
Mol Cell; 2022 Jul; 82(14):2714-2726.e4. PubMed ID: 35649413
[TBL] [Abstract][Full Text] [Related]
35. A functional type II-A CRISPR-Cas system from Listeria enables efficient genome editing of large non-integrating bacteriophage.
Hupfeld M; Trasanidou D; Ramazzini L; Klumpp J; Loessner MJ; Kilcher S
Nucleic Acids Res; 2018 Jul; 46(13):6920-6933. PubMed ID: 30053228
[TBL] [Abstract][Full Text] [Related]
36. Anti-CRISPRs go viral: The infection biology of CRISPR-Cas inhibitors.
Li Y; Bondy-Denomy J
Cell Host Microbe; 2021 May; 29(5):704-714. PubMed ID: 33444542
[TBL] [Abstract][Full Text] [Related]
37. Characterization of a Type II-A CRISPR-Cas System in
Mosterd C; Moineau S
mSphere; 2020 Jun; 5(3):. PubMed ID: 32581075
[No Abstract] [Full Text] [Related]
38. Cell-specific CRISPR-Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins.
Hoffmann MD; Aschenbrenner S; Grosse S; Rapti K; Domenger C; Fakhiri J; Mastel M; Börner K; Eils R; Grimm D; Niopek D
Nucleic Acids Res; 2019 Jul; 47(13):e75. PubMed ID: 30982889
[TBL] [Abstract][Full Text] [Related]
39. A truncated anti-CRISPR protein prevents spacer acquisition but not interference.
Philippe C; Morency C; Plante PL; Zufferey E; Achigar R; Tremblay DM; Rousseau GM; Goulet A; Moineau S
Nat Commun; 2022 May; 13(1):2802. PubMed ID: 35589712
[TBL] [Abstract][Full Text] [Related]
40. Bacteriophage Cooperation Suppresses CRISPR-Cas3 and Cas9 Immunity.
Borges AL; Zhang JY; Rollins MF; Osuna BA; Wiedenheft B; Bondy-Denomy J
Cell; 2018 Aug; 174(4):917-925.e10. PubMed ID: 30033364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
